Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Non-Hodgkin lymphoma
Trial Details
- NCT ID
- NCT06716164
- Phase
- EARLY_PHASE1
- Sponsor
- Zhejiang University
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Metabolically Armed CD19 CAR-T cells
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process;
- Age \> 18 years old, ≤ 70 years old, male or female;
- Diagnosis of relapsed/refractory (R/R) indolent B-cell lymphoma, and/or R/R diffuse large B-cell lymphoma (DLBCL). Refractory diseases are defined …
- Patients with relapsed or refractory B-cell lymphoma treated with one standard treatment regimen and one salvage regimen treated with rituximab or …
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →